4583 Chiome Bioscience
- 132
- 00.00%
Chiome Bioscience News
Chiome Bioscience: Announcements of individual stock: Business partnership about the development of biosimilar pharmaceuticals with KidsWell Bio Co., Ltd.
Chiome Bioscience: Notice regarding the monthly exercise status of the 20th Stock Acquisition Rights (with exercise price amendment clause)
Chiome Bioscience: Presentation of research results using Chiome's antibodies at the 67th Annual Meeting of the Japanese Society of Nephrology
Chiome Bioscience: Announcement of research results using our antibodies at the 67th Annual Meeting of the Japanese Society of Nephrology
CHIOME BIOSCIENCE: Confirmation letter
CHIOME BIOSCIENCE: Quarterly Report - 21st Quarter (2024/01/01 to 2024/03/31)
CHIOME BIOSCIENCE: Financial results supplementary materials 1st quarter of the fiscal year ending 2024/12
CHIOME BIOSCIENCE: Supplementary information on financial results for the 1st quarter of the fiscal year ending December 24
CHIOME BIOSCIENCE: Notice Concerning Completion of Payment of New Shares as Stock Compensation with Transfer Restricted Shares
CHIOME BIOSCIENCE: Unconsolidated financial results for the three months ended March 31, 2024 (Japanese Accounting Standards)
CHIOME BIOSCIENCE: Notice Concerning the Recording of Non-Operating Profit
CHIOME BIOSCIENCE: Summary of financial results for the 1st quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
CHIOME BIOSCIENCE: Notice regarding the monthly exercise status of the 20th Stock Acquisition Rights (with exercise price amendment clause)
CHIOME BIOSCIENCE: Notice Concerning Mass Exercise of the 20th Stock Acquisition Rights (with Exercise Price Amendment Clauses)
Chiome Biosciences: Notice Concerning Issuance of New Shares as Stock Rewards with Transfer Restrictions
Chiome Bioscience: Change Report (Stock Certificates Subject to Special Cases, etc.)
Chiom Bioscience: Notice Concerning the Monthly Exercise Status of the 20th Stock Acquisition Rights (with Exercise Price Amendment Clauses)
Chiome Biosciences: End of license agreement with ADC Therapeutics
Chiom Biosciences: Notice of termination of license agreement with ADC Therapeutics due to transition of ADCT-701 clinical trial subjects to NCI
Chiome Biosciences: Corporate Governance Report 2024/03/26
Analysis
Price Target
No Data
